AstraZeneca Pharma India announced robust financial results for the first quarter of FY2026-27, ending June 30, 2026. Total revenue from operations surged by 30% to INR 6,828 million, fueled by strong performance in core therapy areas like Oncology, Biopharmaceuticals, and Rare Diseases. The company also confirmed the appointment of Mr. Arun Krishna as an Additional Director and a change in Ms. Bhavana Agrawal’s designation.
Strong Q1 Performance Drives Growth
AstraZeneca Pharma India Limited has reported a significant increase in its financial performance for the first quarter of the fiscal year 2026-27, which concluded on June 30, 2026. The company announced a substantial 30% growth in its total revenue from operations, reaching INR 6,828 million. This impressive growth is attributed to disciplined execution across its core therapy areas, including Oncology, Biopharmaceuticals (CVRM and R&I), and Rare Diseases, underscoring the strength of its innovation-led strategy and focus on improving patient outcomes in India.
Key Appointments and Board Decisions
In addition to the strong financial results, the Board of Directors also approved key appointments and changes. Mr. Arun Krishna (DIN: 11876664) has been appointed as an Additional Director (Non-Executive) of the Company, effective August 17, 2026. This appointment follows the recommendation of the Nomination and Remuneration Committee.
Furthermore, the Board approved a change in the designation of Ms. Bhavana Agrawal (DIN: 10485441). Her designation will change from Executive Director to Non-Executive Director, effective September 1, 2026. This change is consequent to her appointment to a regional role within the AstraZeneca Group, following her earlier resignation as Chief Financial Officer.
Financial Highlights and Strategic Initiatives
The unaudited financial results for the quarter ended June 30, 2026, show a profit before exceptional items and tax of INR 510 million, and profit after exceptional items and tax of INR 507 million. The company also highlighted strategic initiatives and key milestones, including regulatory approvals for new treatments and collaborations aimed at expanding access to healthcare solutions.
AstraZeneca Pharma India’s performance reflects its continued focus on addressing unmet medical needs, strengthening its presence across priority therapy areas, and creating long-term value through science and innovation.
Source: BSE
